Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 383 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea and Vomiting Clear all
Completed Not applicable Interventional

Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy

NCT00310063
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
acupressure therapy, sham intervention
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Prospective Controlled Trial On Clear Feeds Versus Low Residue Diet After Surgery In Elective Colorectal Surgery Patients

NCT01890499
View directory record Official record
Conditions
Nausea/Vomiting
Interventions
Low Residue diet arm.
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section

NCT00432991
View directory record Official record
Conditions
Nausea, Vomiting, Cesarean Section
Interventions
Ephedrine [Synonyms: Ephedra, Ephedrinum], Saline Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456
View directory record Official record
Conditions
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Interventions
palonesetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated Phase 4 Interventional Results available

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

NCT03097588
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

NCT01534637
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children

NCT02421952
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 18 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 21, 2026, 9:53 AM EDT
Recruiting Not applicable Interventional

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT05838638
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

NCT00004895
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 21, 2026, 9:53 AM EDT
Withdrawn Phase 3 Interventional

Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)

NCT02506855
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting
Interventions
Ropivacaine, Placebo, Transversus Abdominis Plane Block
Drug · Other · Procedure
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

NCT01757210
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Not listed
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
1 Year to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

NCT02939287
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834
View directory record Official record
Conditions
Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Efficacy of Aprepitant (Emend®) in Children

NCT01661335
View directory record Official record
Conditions
Nausea, Vomiting, Childhood Cancer
Interventions
Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 20 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

NCT01668069
View directory record Official record
Conditions
Vomiting of Pregnancy
Interventions
Ondansetron
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 90 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

NCT02462850
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chemoradiation-Induced Nausea and Emesis: Quality of Life

NCT00394602
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer, Cervical Cancer, Vulvar Cancer, Endometrial Cancer, Anal Cancer
Interventions
Interview, Questionnaire
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jul 21, 2026, 9:53 AM EDT